Abbott Laboratories Corporation

Abbvie Inc.

Makoto, Aoyama

Douglas H Steinman

Steven K Davidsen

James H Holms

James B Summers, Jr

George S Sheppard

Michael Michaelides

Alan S Florjancic

Michael L Curtin

Paul D May

Carol K Wada

Michael R Michaelides

Daisy Pireh

George M Carrera, Jr

James G Phillips

Denise E Guinn

Yan Guo

Yujia Dai

Howard Robin Heyman

Lianhong Xu

Michael B Martin

H Robin Heyman

Jamie R Stacey

Thomas Dale Penning

Stevan Wakefield Djuric

Anna M Ericsson

Lee Daniel Arnold

Stephen W Fesik

Alan Frank Gasiecki

Keith W Woods

Gui-Dong Zhu

Joseph F Dellaria, Jr

Richard W Dixon

Paul Rafferty

Yunsong Tong

Robin R Frey

Jianchun Gong

Irini Akritopoulou-Zanze

Chunqiu Lai

Henry Q Zhang

Zhiren Xia

Jane Gong

Makoto Takeshita

Melanie A Muckey

Magdalena Przytulinska

Vijaya J Gracias

Jürgen Dinges

Kimba Lee Fischer

William J Mcclellan

Lee D Arnold

Aoyama Makoto

Kimba Fischer

4-Amino-N-[3-(diethylamino)propyl]-3-(4-{[(3-fluorophenyl)carbamoyl]amino}phenyl)thieno[3,2-c]pyridine-7-carboxamide which inhibits protein kinases such as Aurora-kinases and the VEGFR and PDGFR families of kinases, with an improved aqueous solubility profile, compositions containing 4-amino-N-[3-(diethylamino)propyl]-3-(4-{[(3-fluorophenyl)carbamoyl]amino}phenyl)thieno[3,2-c]pyridine-7-carboxamide and methods of treating diseases using 4-amino-N-[3-(diethylamino)propyl]-3-(4-{[(3-fluorophenyl)carbamoyl]amino}phenyl)thieno[3,2-c]pyridine-7-carboxamide are disclosed.

Kinase inhibitor with improved solubility profile

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R, R, R, X, and Y are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as Cdc7 and methods of treating diseases such as cancer.

Pyrrolopyridine inhibitors of kinases

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, A, Aand L are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as aurora and KDR.

Indazole inhibitors of kinase

Compounds of the present invention are useful for inhibiting protein tyrosine kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

Tricyclic pyrazole kinase inhibitors

Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

Isoindolinone kinase inhibitors

Reverse hydroxamate inhibitors of matrix metalloproteinases

Macrocyclic compounds of formula ##STR1## are potent inhibitors of matrix metalloproteinase and are useful in the treatment of diseases in which matrix metalloproteinase play a role. Also disclosed are matrix metalloproteinase inhibiting compositions and a method of inhibiting matrix metalloproteinase in a mammal.

Macrocyclic inhibitors of matrix metalloproteinases and TNF.alpha.

Compounds of formula ##STR1## or a pharmaceutically acceptable salt thereof inhibit matrix metalloproteinases and TNF.alpha. secretion and are useful in the treatment of inflammatory disease states. Also disclosed are matrix metalloproteinases and TNF.alpha. secretion inhibiting compositions and a method for inhibiting matrix metalloproteinases and TNF.alpha. secretion.

Biphenyl hydroxamate inhibitors of matrix metalloproteinases

Platelet activating factor antagonists

Benzoylphenyl derivatives of 2-(3-pyridinyl)-3-alkyl-4-thiazolidinecarboxamide, 2-(3-pyridinyl)-thiazolid-4-ylacetamide, 2-(3-pyridinyl)-4-dithiolanecarboxamide or 2-(3-pyridinyl)dithiolan-4-yl]urea-group are potent inhibitors of PAF and are useful in the treatment of PAF-related disorders including anaphylactic shock, respiratory distress syndrome, acute inflammation, delayed cellular immunity, parturtition, fetal lung maturation, and cellular differentiation.

Platelet activating antagonists

Benzoylphenyl derivatives of 2-(3-pyridinyl)-3-alkyl-4-thiazolidinecarboxamide, 2-(3-pyridinyl)-thiazolid-4-ylacetamide, 2-(3-pyridinyl)-4-dithiolanecarboxamide or 2-(3-pyridinyl)dithiolan-4-yl] urea are potent inhibitors of PAF and are useful in the treatment of PAF-related disorders including anaphylactic shock, respiratory distress syndrome, acute inflammation, delayed cellular immunity, parturtition, fetal lung maturation, and cellular differentiation.

Benzoylphenyl pyridinylthiazolidine compounds as platelet activating

Indole compounds substituted at the 1- or 3 position by a (pyrid-3 yl)thiazolid-4-yl)alkyl-, (pyrid-3-yl)thiazolid-4-oyl)-, (pyrid-3-yl)dithiolan-4-yl)alkyl- or (pyrid-3-yl) dithiolan-4-ol)- group are potent inhibitors of PAF and are useful in the treatment of PAF-related disorders including anaphylactic shock, respiratory distress syndrome, acute inflammation, delayed cellular immunity, parturtition, fetal lung maturation, and cellular differentiation.

Growing community of inventors

Morton Grove, IL, United States of America

Douglas H Steinman